Traversa Secures $5M in Series B, Nears Close of Research Deals for Delivery Technology
April 02, 2009
Traversa Secures $5M in Series B, Nears Close of Research Deals for Delivery Technology
The company also plans to begin a series of non-human primate studies to test its delivery technology, a move that is largely driven by the demands of potential big pharma partners for better data before forming alliances.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Tekmira Delays Start of Cancer Drug Trial, Sees Expanded Roche Partnership in '09
March 26, 2009 / Gene Silencing News - Lorus Therapeutics and Ohio State U Partner on Nanoparticle Delivery of siRNA Cancer Rx
March 25, 2009 / - Cenix Begins Building In Vivo Research Operations, Developing siRNA Delivery Tech
April 30, 2009 / Gene Silencing News - IP Update
April 30, 2009 / Gene Silencing News - NCI to Expand TCGA to Up to 25 Tumor Types; Use Next-Gen Sequencing on Childhood Cancers
April 28, 2009 / In Sequence